If you are interested in the interface between cancer immunotherapy innovation and photonics, then catch up with Tomas Hode, PhD, co-founder, CIO, and President of Immunophotonics, Inc. in person at SPIE, the international society for optics and photonics conferences #PhotonicsWest / #BiOS 2022 Jan 22 – 27 in San Francisco. He and Lu Alleruzzo (CEO)...
Immunophotonics is pleased to announce that the United States Patent and Trademark has issued U.S. Patent No. 11111316, which covers the composition of matter of its proprietary synthetic biopolymer, IP-001. Immunophotonics is currently conducting clinical studies for the use of IP-001 to treat various metastatic cancer indications and is exploring other applications of the drug...
Immunophotonics Switzerland (IPS Biopharma) will be presenting at the Swiss Biotech Day in the Emerging Company session hosted by BB Pureos Bioventures. The Swiss Biotech Day is one of the premier annual biotechnology conferences in Europe, featuring panel discussions and presentations from key opinion leaders in the biotech industry. Immunophotonics’ presentation will take place on...
Immunophotonics is excited to be featured in the September 2021 oncology issue of Nature Biopharma Dealmakers. Read what Dr. Markus Joerger and Dr. David Anderson, distinguished clinical and scientific experts, have to say about how Immunophotonics is pioneering the growing field of Interventional Immuno-Oncology (IIO) with its lead drug candidate, IP-001. To read the article,...
Immunophotonics has been featured in the March oncology issue of Nature Biopharma Dealmakers (https://www.nature.com/articles/d43747-021-00020-2 ). Nature selects only a handful of companies for such articles. The article highlights our uniqueness in pioneering Interventional Immuno-Oncology and conveys some of our recent findings.
A paper recently published in Cells has described how Immunophotonics’ immune-stimulating drug IP-001 was shown to be effective against metastatic tumors when combined with different forms tumor ablation. In this review, the authors briefly discuss the current applications of local ablation for cancer treatment and the effects of IP-001 in combination with other ablation therapies,...
ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) — Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated solid tumors. The trial, conducted in collaboration with the Swiss Group for Clinical Cancer Research (SAKK), will assess the safety, tolerability and anti-tumor activity of IP-001...
OU Daily at the University of Oklahoma recently published a story on research being conducted by Dr. Wei R. Chen on IP-001’s potential application as an immune-system booster that could be used in conjunction with a COVID-19 vaccine. The story is available here.
October 05, 2020 04:13 ET | Source: Immunophotonics, Inc. BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) — Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of solid and metastatic cancers, has bolstered its expertise through the appointment of Jonathan Knowles, Ph.D. to its Board...
Immunophotonics has received Swissmedic approval to commence a new clinical trial entitled “Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.” This is a multicenter phase 1B/2A trial with expansion cohorts in melanoma and soft tissue sarcoma patients. The therapeutic approach taken by this trial (SAKK 66/17) is different from those...
